Peptide Drug Advances Being Made on Syracuse University Campus Working to Redefine Obesity, Diabetes Care
Over the past 18 months, Robert Doyle, a medicinal chemist and the Jack and Laura H. Milton Professor of Chemistry in the College of Arts and Sciences at Syracuse University, introduced two new peptide compound discoveries at conferences of the American Chemical Society (ACS) and The Obesity Society. He and his collaborators reported that the compounds notably reduce body weight and normalize blood glucose levels without the typical negative side effects experienced by many patients who take currently available GLP-1-based anti-obesity drugs.
GEP44
Doyle and his fellow researchers have since worked on refining the compound, GEP44, and have undertaken lab-animal testing, filed patents, spoken with investors and explored market placement. They believe this compound, ultimately intended for use in humans, will offer significant advances in how obesity and diabetes are treated in the U.S. and around the world. The researchers have also discovered another highly promising weight-loss compound and new outgrowths that have potential to treat opioid addiction through similar neuroendocrine pathways.
